Daniel O'Connell, CEO of Acumen Pharmaceuticals, on Oligomers, Innovation, and Hope in Alzheimer’s
Update: 2025-09-05
Description
With over 25 years of experience building and investing in CNS companies, Daniel shares the story of why he placed a big bet on Acumen — from its origins as a seed-stage idea to today’s phase 2 clinical trial, Altitude AD. He explains the science behind targeting amyloid beta oligomers (rather than plaques), what makes Alzheimer’s research uniquely difficult, and why recent advances in biomarkers, trial design, and patient recruitment give him hope for meaningful progress.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
